TUKYSA under the microscope: how safe is it in everyday use?
NCT ID NCT06873191
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study tracks 600 adults in Korea with advanced HER2-positive breast cancer who are starting TUKYSA for the first time. Researchers will monitor how well the drug works and any side effects in real-world settings, outside of controlled trials. The goal is to confirm the drug's safety and effectiveness as part of a required post-approval review.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
TUKYSA (tucatinib)
What this could lead to
If successful, this study will confirm that TUKYSA works safely in everyday clinical practice, supporting its continued use for advanced HER2+ breast cancer.
What could go wrong
This is an observational study, not a new treatment test. It only monitors existing use, so it won't discover new cures or major breakthroughs. Results may be limited to Korean patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••